FDA Granted Designation to Scoliosis Blood Test
The ScolimiR-3D test, designed to predict spinal curve progression, has received FDA Breakthrough Device status.
Updated on Sept. 29, 2026 in Life Sciences
Live Poll
Do you believe early predictive diagnostic blood tests lead to better long-term health outcomes for patients?
The FDA has granted Breakthrough Device Designation to the ScolimiR-3D test, a diagnostic tool that assesses the risk of disease progression in patients with adolescent idiopathic scoliosis. This research-stage test is the first predictive diagnostic for scoliosis to receive this status.
Why it matters
Physicians currently lack definitive tools to identify which scoliosis patients will experience severe disease progression, a gap this technology aims to fill. By predicting outcomes early, clinicians may be able to better tailor intervention strategies for those at risk.
The diagnostic panel measures six circulating microRNAs—small, non-coding RNA molecules that regulate gene expression—to classify a patient's risk profile. The test achieved 100% sensitivity and specificity in a validated cohort of 116 patients.
The players
FDA
The United States federal agency responsible for regulating medical devices and ensuring the safety and effectiveness of diagnostic tests.
Scoliosis Research Society
A global professional organization dedicated to research and education in the treatment of spinal deformities.
The details
ScolimiR-3D operates via a standard blood draw to detect specific microRNA biomarkers in the bloodstream. By quantifying these six genetic markers, the test classifies whether a patient with adolescent idiopathic scoliosis is likely to develop a severe spinal curve. The underlying methodology was validated in a study published in Scientific Reports, and the test is currently classified as a device in development.
Timeline
February 12, 2025: Underlying science published in Scientific Reports.
September 29, 2026: FDA Breakthrough Device Designation announced.
October 6-10, 2026: Additional research expected at the Scoliosis Research Society 2026 Annual Meeting.
The Tech Race
The development follows a pattern set by other novel molecular diagnostics aiming for validation at specialized clinical conferences like the Scoliosis Research Society 2026 Annual Meeting. It marks a significant shift toward using liquid biopsies for pediatric orthopedic risk stratification.
This test is not yet available for clinical use, and patients or families should consult their physicians regarding existing diagnostic standards. It is intended to eventually provide a non-invasive way for clinicians to determine the necessity of early intervention for spinal conditions.
The takeaway
The ScolimiR-3D test represents a shift toward predictive molecular diagnostics in pediatric spine care. Observers should track upcoming results from the Scoliosis Research Society 2026 Annual Meeting for further data on the performance of this six-microRNA panel.
What happens next
Additional research is expected to be presented at the Scoliosis Research Society 2026 Annual Meeting, scheduled for October 6-10, 2026, in Sydney.
Further reading
For more on the latest research in diagnostic technology, visit our Life Sciences section.
More information
For more details on the underlying research, visit the VB Spine company website.
Live Poll
Do you believe early predictive diagnostic blood tests lead to better long-term health outcomes for patients?
